MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

Paradigm Biopharmaceuticals continues to edge closer towards starting the pivotal phase III trial for its knee osteoarthritis ...

Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...

KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the ...

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Paradigm Biopharmaceuticals has selected Advanced Clinical as the CRO to support its Phase III trial, PARA_OA_012, focused on ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

“We are delighted to partner with Advanced Clinical for our pivotal phase III clinical trial, PARA_OA_012,” managing director Paul Rennie said. “Advanced Clinical’s expertise in clinical ...

Phase III trials aim to confirm the safety and effectiveness of groundbreaking treatments, bringing hope for new therapies to tackle often challenging medical conditions with limited therapeutic ...

"Assuming successful completion and results from this Phase III clinical trial, this drug’s expanded indication will give us access to a new patient base and enable the delivery of a therapy to ...

Canaccord rates Opthea a buy with a $1.25 price target. But the broker thinks it could shoot as high as $3 if a key trial ...